Novartis confident of Zolgensma supply, calls $2 million price "speculation" - (NASDAQ via NewsPoints Desk)

  • David Lennon, who heads Novartis' Zolgensma development programme, expressed confidence that the drugmaker has sufficient production capacity to meet demand for the therapy, as reported NASDAQ Wednesday.

  • Novartis expects the drug to be approved by the FDA this month.

  • Meanwhile, Lennon dismissed media reports that Novartis would price the drug at $2 million as "complete speculation."

  • Novartis, which acquired Zolgensma via its $8.7-billion takeover of AveXis last year, previously indicated that the treatment could be priced at $1.5 million to $5 million per patient.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.